Immutep
Immutep
IMMP
NASDAQ
1.78
USD
1.71%
About
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer.
IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer.
Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 127.2K |
| Three Month Average Volume | 7.6M |
| High Low | |
| Fifty-Two Week High | 3.335 USD |
| Fifty-Two Week Low | 1.58 USD |
| Fifty-Two Week High Date | 21 May 2024 |
| Fifty-Two Week Low Date | 21 Nov 2023 |
| Price and Volume | |
| Current Price | 2.63 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 24.47% |
| Thirteen Week Relative Price Change | -17.54% |
| Twenty-Six Week Relative Price Change | 4.00% |
| Fifty-Two Week Relative Price Change | 10.47% |
| Year-to-Date Relative Price Change | -7.46% |
| Price Change | |
| One Day Price Change | 6.05% |
| Thirteen Week Price Change | -11.74% |
| Twenty-Six Week Price Change | 14.35% |
| Five Day Price Change | 8.23% |
| Fifty-Two Week Price Change | 38.42% |
| Year-to-Date Price Change | 9.58% |
| Month-to-Date Price Change | 21.76% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.7703 USD |
| Book Value Per Share (Most Recent Quarter) | 0.65245 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.71673 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.60314 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.28831 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00144 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00165 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.29964 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.26393 USD |
| Normalized (Last Fiscal Year) | -0.29964 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.29964 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.26393 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.29964 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.26393 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.69663 USD |
| Cash Per Share (Most Recent Quarter) | 0.58527 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.28261 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.24694 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.27172 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -16,456 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -15,782.59% |
| Pretax Margin (Last Fiscal Year) | -20,809.70% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -23,411.41% |
| Operating Margin (Trailing Twelve Months) | -18,287.58% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -20,809.70% |
| Net Profit Margin (Trailing Twelve Months) | -15,782.59% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 270.42% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -0.14% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -70.88% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 22.94% |
| EPS Change (Trailing Twelve Months) | 5.11% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -69,073,760 |
| Net Debt (Last Fiscal Year) | -82,648,660 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3.1K |
| Price to Sales (Trailing Twelve Months) | 2.3K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 1 |
| Long Term Debt to Equity (Most Recent Quarter) | 1 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 |
| Current Ratio (Most Recent Quarter) | 17 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,970,560 |
| Free Cash Flow (Trailing Twelve Months) | -28,564,260 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1 |
| Total Debt to Equity (Most Recent Quarter) | 1 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -31.97% |
| Return on Assets (Trailing Twelve Months) | -38.61% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -34.61% |
| Return on Equity (Trailing Twelve Months) | -42.12% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -34.18% |
| Return on Investment (Trailing Twelve Months) | -41.57% |
| Return on Investment (5 Year) | -99,999.99% |